New paper by Dr. Francesco Bertoni lab

news on 31 Oct , 2017
The study, published in Clinical Cancer Research journal, describes the preclinical in vitro and in vivo activity of the novel dual PI3K/mTOR inhibitor PQR309 (bimiralisib) in lymphoma. http://clincancerres.aacrjournals.org/content/early/2017/10/24/1078-0432.CCR-17-1041 PQR309 is a novel dual PI3K/mTOR inhibitor with pre-clinical antitumor activity in lymphomas as a single agent and in combi...
More

New paper by Dr. Jean-Philippe Theurillat Lab

news on 21 Sep , 2017
The publication in the renowned scientific journal Nature Medicine describes how the degradation of BET proteins are regulated by point mutations in the ubiquitin ligase adaptor protein SPOP and how this affects the sensitivity to BET protein inhibitors - a class of chromatin interacting small molecules that are currently in clinical development. Article: Opposing effects of cancer type-spec...
More

Dr. Giuseppina Carbone presented at the European Association of Urology in London

news on 18 May , 2017
Dr. Giuseppina Carbone presented at the European Association of Urology in London (EAU17,24-28 March,London) at the Thematic session on personalized medicine in prostate cancer. Knowledge of overexpressed oncogenes and the importance of the transcription factor ETS-related gene (ERG) and cytokines in relation to individualised therapy in prostate cancer, were examined today during the “Personal...
More